Trends Mol Med. 2007 Jul;13(7):298-309. Epub 2007 Jun 27. Targeting farnesoid X receptor for liver and metabolic disorders. Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Dipartimento di Medicina Clinica e Sperimentale, University of Perugia, Perugia, Italy. fiorucci@unipg.it Abstract The farnesoid X receptor (FXR) is a metabolic nuclear receptor expressed in the liver, intestine, kidney and adipose tissue. By regulating the expression and function of genes involved in bile acid (BA) synthesis, uptake and excretion, FXR has emerged as a key gene involved in the maintenance of cholesterol and BA homeostasis. FXR ligands are currently under clinical investigation for the treatment of cholestasis, dyslipidemic disorders and conditions of insulin resistance in type 2 diabetes and non-alcoholic steatohepatitis (NASH). Because activation of FXR impacts a considerable number of genes, development of FXR modulators that selectively regulate specific pathways will limit potentially undesirable side effects. Interaction of FXR with other BAs and xenobiotics sensors such as the constitutive androstane receptor and the pregnane X receptor might allow the development of combination therapies for liver and metabolic disorders. PMID: 17588816 [PubMed - indexed for MEDLINE]
Targeting farnesoid X receptor for liver and metabolic disorders.
FIORUCCI, Stefano;DONINI, Annibale;
2007
Abstract
Trends Mol Med. 2007 Jul;13(7):298-309. Epub 2007 Jun 27. Targeting farnesoid X receptor for liver and metabolic disorders. Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Dipartimento di Medicina Clinica e Sperimentale, University of Perugia, Perugia, Italy. fiorucci@unipg.it Abstract The farnesoid X receptor (FXR) is a metabolic nuclear receptor expressed in the liver, intestine, kidney and adipose tissue. By regulating the expression and function of genes involved in bile acid (BA) synthesis, uptake and excretion, FXR has emerged as a key gene involved in the maintenance of cholesterol and BA homeostasis. FXR ligands are currently under clinical investigation for the treatment of cholestasis, dyslipidemic disorders and conditions of insulin resistance in type 2 diabetes and non-alcoholic steatohepatitis (NASH). Because activation of FXR impacts a considerable number of genes, development of FXR modulators that selectively regulate specific pathways will limit potentially undesirable side effects. Interaction of FXR with other BAs and xenobiotics sensors such as the constitutive androstane receptor and the pregnane X receptor might allow the development of combination therapies for liver and metabolic disorders. PMID: 17588816 [PubMed - indexed for MEDLINE]I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
